New Perspectives on Chronic Obstructive Pulmonary Disease

References

• Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365.
   PubMed Web of Science ®Google Scholar
• Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019;381:1257–1266.
   PubMed Web of Science ®Google Scholar
• Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2022. Available From: https://goldcopd.org/wp-content/uploads/2021/11/GOLD-REPORT-2022-v1.0-12Nov2021_WMV.pdf. Accessed November 2021.
   Google Scholar
• Agusti A. The path to personalised medicine in COPD. Thorax. 2014;69:857–864.
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1:1645–1648.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA. 1994;272:1497–1505.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Srensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819–1823.
   PubMed Web of Science ®Google Scholar
• Pauwels RA. Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking. N Engl J Med. 1999;340:1948.
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–1303.
   PubMed Web of Science ®Google Scholar
• Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902–1909.
   PubMed Web of Science ®Google Scholar
• Decramer M, Lken M, Dekhuijzen PNR, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (BronchitisRandomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365:1552–1560.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554.
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332–338.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95–99.
   PubMed Web of Science ®Google Scholar
• Casanova C, de Torres JP, Aguirre-Jaíme A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184:1015–1021.
   PubMed Web of Science ®Google Scholar
• Celli BR, Anderson JA, Cowans NJ, et al. Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. Am J Respir Crit Care Med. 2021;203:689–698.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555.
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017;49:1700214.
   PubMed Web of Science ®Google Scholar
• Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2019. Available From: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed August 18, 2021.
   Google Scholar
• Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020. Available From: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed August 18, 2021.
   Google Scholar
• Celli BR, Agustí A. COPD: time to improve its taxonomy?. ERJ Open Res. 2018;4:132–2017.
   PubMedGoogle Scholar
• Lange P, Celli B, Agustí A, et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med. 2015;373:111–122.
   PubMed Web of Science ®Google Scholar
• Agustí A, Noell G, Brugada J, et al. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med. 2017;5:935–945.
   PubMed Web of Science ®Google Scholar
• Singh D, Barnes PJ, Stockley R. Pharmacological treatment of COPD: the devil is always in the detail. Eur Respir J. 2018;51:1800263.
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Chapman KR, Donohue JF, et al. Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. Pulm Ther. 2019;5:23–41.
   PubMedGoogle Scholar
• Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18:67.
   PubMed Web of Science ®Google Scholar
• Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140:331–342.
   PubMed Web of Science ®Google Scholar
• Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe?. Eur Respir J. 2018;52(6):1801219.
   PubMed Web of Science ®Google Scholar
• Rutgers SR, Timens W, Kaufmann HF, et al. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur Respir J. 2000;15:109–115.
   PubMed Web of Science ®Google Scholar
• Kolsum U, Damera G. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017;140:1181–1184.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356:1480–1485.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–126.
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, et al.; on behalf of the ECLIPSE investigators. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;1(44):1697–1700.
   Web of Science ®Google Scholar
• Casanova C, Celli BR, de-Torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50:1701162.
   PubMed Web of Science ®Google Scholar
• Southworth T, Beech G, Foden P, Kolsum U, Singh D. The reproducibility of COPD blood eosinophil counts. Eur Respir J. 2018;52(1):1800427. doi:10.1183/13993003.00427-2018
   PubMed Web of Science ®Google Scholar
• Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076–1084.
   PubMed Web of Science ®Google Scholar
• Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48:320–330.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378:1671–1680.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al.; ETHOS Investigators. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383:35–48.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018;6:337–344.
   PubMed Web of Science ®Google Scholar
• Sethi S, Kerwin E, Watz H, et al. AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of Aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:667–682.
   PubMed Web of Science ®Google Scholar
• Wise RA, Chapman KR, Scirica BM, et al. Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: the ASCENT-COPD Randomized Clinical Trial. JAMA. 2019;321:1693–1701.
   PubMed Web of Science ®Google Scholar
• Sanchez-Salcedo P, Divo M, Casanova C, Pinto-Plata V. Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. Eur Respir J. 2014;44:324–331.
   PubMed Web of Science ®Google Scholar
• Çolak Y, Afzal S, Nordestgaard BG, et al. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med. 2017;5:426–434.
   PubMed Web of Science ®Google Scholar
• Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet. 2009;374:721–732.
   PubMed Web of Science ®Google Scholar
• Labonte LE, Tan WC, Li PZ, et al. Undiagnosed COPD contributes to the burden of health care utilization: data from the CanCOLD Study. Am J Respir Crit Care Med. 2016;194:285–298.
   PubMed Web of Science ®Google Scholar
• Martinez CH, Mannino DM, Jaimes FA, et al. Undiagnosed obstructive lung disease in the United States. Associated factors and long-term mortality. Ann Am Thorac Soc. 2015;12:1788–1795.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Mannino D, Leidy NK, et al.; High-Risk-COPD Screening Study Group. A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;195(6):748–756.
   PubMed Web of Science ®Google Scholar
• Agusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir Med. 2019;7:358–364.
   PubMed Web of Science ®Google Scholar
• Agusti A, Faner R, Donaldson G, et al. Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration. Eur Respir J. 2019;53:1900217.
   PubMed Web of Science ®Google Scholar
• Oelsner EC, Smith BM, Hoffman EA, et al. Associations between emphysema-like lung on CT and incident airflow limitation: a general population-based cohort study. Thorax. 2018;73:486–488.
   PubMed Web of Science ®Google Scholar
• Allinson JP, Hardy R, Donaldson GC, et al. The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development. Am J Respir Crit Care Med. 2016;193:662–672.
   PubMed Web of Science ®Google Scholar
• Petersen H, Sood A, Polverino F, et al. The Course of Lung Function in Middle-aged Heavy Smokers: incidence and Time to Early Onset of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018;198:1449–1451.
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Celli BR, et al. From GOLD 0 to Pre-COPD. Am J Respir Crit Care Med. 2021;203:414–423.
   PubMed Web of Science ®Google Scholar
• Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47:410–419.
   PubMed Web of Science ®Google Scholar
• Dransfield M, Stolz D, Kleinert S; Lancet COPD Commissioners. Towards eradication of chronic obstructive pulmonary disease: a Lancet Commission. Lancet. 2019;393:1786–1788.
   PubMed Web of Science ®Google Scholar